Print Friendly

Robert Hauser, MD, MBA

Director, College Of Medicine Neurology

Professor, College Of Medicine Neurology

Director, Parkinson's Disease and Movement Disorde, Neurology, University of South Florida

Professor, Neurology, University of South Florida

Contact Info 4001 E. Fletcher Ave
6th Floor
Tampa, FL 33613

Academic Email: rhauser@health.usf.edu

Academic Phone: (813) 396-0765


  • MBA, Business Administration, University of South Florida, 2000
  • MD, Medicine, Temple University, 1982

Interdisciplinary and Emerging Signature Programs

  • Neuroscience


  • American Academy of Neurology (Fellow, 2004 - Present)
  • Movement Disorders Society (Member, 1988 - Present)
  • American Academy of Neurology (Member, 1988 - Present)

Recent Publications

  • 235. Hauser RA, Silver D, Choudhry A, Eyal E, Isaacson S, for the ANDANTE study investigators. Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson’s disease Mov Disord. 29(8) : 1028-34, 2014.
  • Goldman SM, Kamel F, Ross GW, Jewell SA, Marras C, Hoppin JA, Umbach DM, Bhudhikanok GS, Meng C, Korell M, Comyns K, Hauser RA, Jankovic J, Factor SA, Peptidoglycan recognition protein genes and risk of Parkinson's disease. Mov Disord. 29(9) : 1171-80, 2014.
  • Hauser RA, Schapira AH, Barone P, Mizuno Y, Rascol O, Busse M, Debieuvre C, Fraessdorf M, Poewe W Pramipexole ER Studies Group.Long-term safety and sustained efficacy of extended-release pramipexole in early and advanced Parkinson's disease. Eur J Neurol. 21(5) : 736-43, 2014.
  • Hauser RA, Gordon MF, Mizuno Y, Poewe W, Barone P, Schapira AH, Rascol O, Debieuvre C, Fräßdorf M. Minimal clinically important difference in Parkinson's disease as assessed in pivotal trials of pramipexole extended release. Parkinsons Dis. , 2014.
  • Kremens, D.Hauser, RA.Dorsey, ER. An update on Parkinson's disease: improving patient outcomes. The American journal of medicine. 127(1) : S3, 2014. http://www.ncbi.nlm.nih.gov/pubmed/24384115
  • The Parkinson Study Group QE3 Investigators (including Hauser RA). A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease: No Evidence of Benefit. JAMA Neurol. 71(5) : 543-52, 2014.
  • 229. Low PA, Robertson D, Gilman S, Kaufmann H, Singer W, Biaggioni I, Freeman R, Perlman S, Hauser RA, Cheshire W, Lessig S, Vernino S, Mandrekar J, Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 13(3) : 268-75, 2014.
  • Pahwa, R.Lyons, KE.Hauser, RA.Fahn, S.Jankovic, J.Pourcher, E.Hsu, A.O'Connell, M.Kell, S.Gupta, S. Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease. Parkinsonism & related disorders. 20(2) : 142-8, 2014. http://www.ncbi.nlm.nih.gov/pubmed/24055014
  • Cicchetti F, Lacroix S, Cisbani G, Vallières N, Saint-Pierre M, St-Amour I, Tolouei R, Skepper J, Hauser R, Mantovani D, Barker R, Freeman T. Mutant huntingtin is present in neuronal grafts in Huntington's disease patients. Ann Neurol. 76(1) : 31-42, 2014.
  • Cisbani, G.Freeman, TB.Soulet, D.Saint-Pierre, M.Gagnon, D.Parent, M.Hauser, RA.Barker, RA.Cicchetti, F. Striatal allografts in patients with Huntington's disease: impact of diminished astrocytes and vascularization on graft viability. Brain : a journal of neurology. 136(Pt 2) : 433-43, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23378216
  • The Parkinson Study Group (including Hauser RA). Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD) Mov Disord. 28(13) : 1823-31, 2013.
  • Schapira, AH.Barone, P.Hauser, RA.Mizuno, Y.Rascol, O.Busse, M.Debieuvre, C.Fraessdorf, M.Poewe, W. Patient-reported convenience of once-daily versus three-times-daily dosing during long-term studies of pramipexole in early and advanced Parkinson's disease. European journal of neurology : the official journal of the European Federation of Neurological Societies. 20(1) : 50-6, 2013. http://www.ncbi.nlm.nih.gov/pubmed/22537207
  • Schapira, AH.Barone, P.Hauser, RA.Mizuno, Y.Rascol, O.Busse, M.Debieuvre, C.Fraessdorf, M.Poewe, W. Success rate, efficacy, and safety/tolerability of overnight switching from immediate- to extended-release pramipexole in advanced Parkinson's disease. European journal of neurology : the official journal of the European Federation of Neurological Societies. 20(1) : 180-7, 2013. http://www.ncbi.nlm.nih.gov/pubmed/22845710
  • Hauser, RA.Truong, D.Hubble, J.Coleman, C.Beffy, JL.Chang, S.Picaut, P. AbobotulinumtoxinA (Dysport) dosing in cervical dystonia: an exploratory analysis of two large open-label extension studies. Journal of neural transmission (Vienna, Austria : 1996). 120(2) : 299-307, 2013. http://www.ncbi.nlm.nih.gov/pubmed/22878514
  • Fernandez, HH.Vanagunas, A.Odin, P.Espay, AJ.Hauser, RA.Standaert, DG.Chatamra, K.Benesh, J.Pritchett, Y.Hass, SL.Lenz, RA. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results. Parkinsonism & related disorders. 19(3) : 339-45, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23287001
  • HORIZON Investigators of the Huntington Study Group and European Huntington's Disease Network. A randomized, double-blind, placebo-controlled study of latrepirdine in patients with mild to moderate Huntington disease JAMA Neurol. 70(1) : 25-33, 2013.
  • Goetz, CG.Stebbins, GT.Chung, KA.Hauser, RA.Miyasaki, JM.Nicholas, AP.Poewe, W.Seppi, K.Rascol, O.Stacy, MA.Nutt, JG.Tanner, CM.Urkowitz, A.Jaglin, JA.Ge, S. Which dyskinesia scale best detects treatment response? Movement disorders : official journal of the Movement Disorder Society. 28(3) : 341-6, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23390076
  • Hauser, RA.Hsu, A.Kell, S.Espay, AJ.Sethi, K.Stacy, M.Ondo, W.O'Connell, M.Gupta, S. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet neurology. 12(4) : 346-56, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23485610
  • Bajaj, N.Hauser, RA.Grachev, ID. Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes. Journal of neurology, neurosurgery, and psychiatry. 84(11) : 1288-95, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23486993
  • Factor, SA.Wolski, K.Togasaki, DM.Huyck, S.Cantillon, M.Ho, TW.Hauser, RA.Pourcher, E. Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society. 28(6) : 817-20, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23589371
  • Hauser, RA. PROUD stands tall: delayed-start studies in Parkinson's disease. Lancet neurology. 12(8) : 728-9, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23726852
  • Stocchi, F.Rascol, O.Destee, A.Hattori, N.Hauser, RA.Lang, AE.Poewe, W.Stacy, M.Tolosa, E.Gao, H.Nagel, J.Merschhemke, M.Graf, A.Kenney, C.Trenkwalder, C. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Movement disorders : official journal of the Movement Disorder Society. 28(13) : 1838-46, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23853029
  • Kumar, R.Hauser, RA.Mostillo, J.Dronamraju, N.Graf, A.Merschhemke, M.Kenney, C. Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients. The International journal of neuroscience. , 2013. http://www.ncbi.nlm.nih.gov/pubmed/24007304
  • Edwards, JD.Hauser, RA.O'Connor, ML.Valdés, EG.Zesiewicz, TA.Uc, EY. Randomized trial of cognitive speed of processing training in Parkinson disease. Neurology. 81(15) : 1284-90, 2013. http://www.ncbi.nlm.nih.gov/pubmed/24014503
  • Nutt, JG.Siderowf, AD.Guttman, M.Schmidt, PN.Zamudio, JI.Wu, SS.Okun, MS.Simuni, T.Parashos, SA.Dahodwala, NA.Davis, TL.Giladi, N.Gurevich, T.Hauser, RA.Jankovic, J.Lyons, KE.Marsh, L.Miyasaki, JM.Morgan, JC.Santiago, AJ.Tarsy, D.Mari, Z.Malaty, IA.Nelson, EC. Mobility, mood and site of care impact health related quality of life in Parkinson's disease. Parkinsonism & related disorders. , 2013. http://www.ncbi.nlm.nih.gov/pubmed/24182524
  • Hauser, RA.Hewitt, LA.Isaacson, S. Droxidopa in Patients with Neurogenic Orthostatic Hypotension Associated with Parkinson's Disease (NOH306A). Journal of Parkinson's disease. : 57-65, 2013. http://www.ncbi.nlm.nih.gov/pubmed/24326693
  • Lewitt, PA.Huff, FJ.Hauser, RA.Chen, D.Lissin, D.Zomorodi, K.Cundy, KC. Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society. , 2013. http://www.ncbi.nlm.nih.gov/pubmed/24339234
  • Charles, D.Brashear, A.Hauser, RA.Li, HI.Boo, LM.Brin, MF. Efficacy, tolerability, and immunogenicity of onabotulinumtoxina in a randomized, double-blind, placebo-controlled trial for cervical dystonia. Clinical neuropharmacology. 35(5) : 208-14, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22948497
  • Morelli, M.Blandini, F.Simola, N.Hauser, RA. A(2A) Receptor Antagonism and Dyskinesia in Parkinson's Disease. Parkinson's disease. 2012: 489853, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22754707
  • Lewitt, PA.Hauser, RA.Lu, M.Nicholas, AP.Weiner, W.Coppard, N.Leinonen, M.Savola, JM. Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study). Neurology. 79(2) : 163-9, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22744665
  • Hauser, RA.Lyons, KE.Pahwa, R. The UPDRS-8: a brief clinical assessment scale for Parkinson's disease. The International journal of neuroscience. 122(7) : 333-7, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22329569
  • Elm JJ; The NINDS NET-PD Investigators Design innovations and baseline findings in a long-term Parkinson’s trial: The national institute of neurological disorders and stroke exploratory trials in Parkinson’s Disease Long-Term Study-1 Mov Disord. 12(27) : 1513-1521, 2012.
  • Rascol, O.Bronzova, J.Hauser, RA.Lang, AE.Sampaio, C.Theeuwes, A.van de Witte, SV. Pardoprunox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial. Parkinsonism & related disorders. 18(4) : 370-6, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22316635
  • Hauser, RA. IPX066: a novel carbidopa-levodopa extended-release formulation. Expert review of neurotherapeutics. 12(2) : 133-40, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22288668
  • Goldman, SM.Kamel, F.Ross, GW.Jewell, SA.Bhudhikanok, GS.Umbach, D.Marras, C.Hauser, RA.Jankovic, J.Factor, SA.Bressman, S.Lyons, KE.Meng, C.Korell, M.Roucoux, DF.Hoppin, JA.Sandler, DP.Langston, JW.Tanner, CM. Head injury, α-synuclein Rep1, and Parkinson's disease. Annals of neurology. 71(1) : 40-8, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22275250
  • Hauser, RA.Grosset, DG. [123I]FP-CIT (DaTscan) SPECT brain imaging in patients with suspected parkinsonian syndromes. Journal of neuroimaging : official journal of the American Society of Neuroimaging. 22(3) : 225-30, 2012. http://www.ncbi.nlm.nih.gov/pubmed/21410815
  • Mizuno, Y.Yamamoto, M.Kuno, S.Hasegawa, K.Hattori, N.Kagimura, T.Sarashina, A.Rascol, O.Schapira, AH.Barone, P.Hauser, RA.Poewe, W. Efficacy and safety of extended- versus immediate-release pramipexole in Japanese patients with advanced and L-dopa-undertreated Parkinson disease: a double-blind, randomized trial. Clinical neuropharmacology. 35(4) : 174-81, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22801294
  • Hauser RA, Ellenbogen AL, Metman LV, Hsu A, O'Connell MJ, Modi NB, Yao HM, Kell SH, Gupta SK Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease Mov Disord. 12(26) : 2246-52, 2011.
  • Poewe W, Rascol O, Barone P, Hauser RA, Mizuno Y, Haaksma M, Salin L, Juhel N, Schapira AH Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial Neurology. 8(77) : 759-66, 2011.
  • Hauser, RA.Cantillon, M.Pourcher, E.Micheli, F.Mok, V.Onofrj, M.Huyck, S.Wolski, K. Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial. Lancet neurology. 10(3) : 221-9, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21315654
  • Friedman JH, Agarwal P, Alcalay R, Black KJ, Chou KL, Cote L, Dayalu P, Frank S, Hartlein J, Hauser RA, Lang AE, Marsh L, Marshall F, Moskowitz C, Ravina B, Riley D, Sanchez-Ramos J, Simon DK, Simuni T, Sutton J, Tuite P, Weintraub D, Zesiewicz T Clinical vignettes in Parkinson's disease: a collection of unusual medication-induced hallucinations, delusions, and compulsive behaviours. Int J Neurosci.. 8(121) : 767-74, 2011.
  • Hauser RA Future treatments for Parkinson’s disease: surfing the PD pipeline Int J Neurosci.. 2(121) : 53-62, 2011.
  • Gross RE, Watts RL, Hauser RA, Bakay RA, Reichmann H, von Kummer R, Ondo WG, Reissig E, Eisner W, Steiner-Schulze H, Siedentop H, Fichte K, Hong W, Cornfeldt M, Beebe K, Sandbrink R; the Spheramine Investigational Group Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson's disease: a double-blind, randomised, controlled trial Lancet Neurol. 6(10) : 509-519, 2011.
  • Rascol, O., Fitzer-Attas, C.J., Hauser, R., Jankovic, J., Lang, A., Langston, J. W., …& Olanow, C. W. A double-blind, delayed-start trial of rasgiline in Parkinson’s disease (the ADAGIO study) : prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. The Lancet Neurology. 5(10) : 415-423, 2011.
  • Sampaio C, Bronzova J, Hauser RA, Lang AE, Rascol O, van de Witte SV, Theeuwes AA; for the Rembrandt/Vermeer Study Groups Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double-blind trials. Mov Disord. 8(26) : 1464-76, 2011.
  • Hauser RA, Reichmann H, Lew M, Asgharian A, Makumi C, Shulman KJ Long-term, Open-label Study of Once-daily Ropinirole Prolonged Release in Early Parkinson's Disease. Int J Neurosci. 5(121) : 246-53, 2011.
  • Hauser RA, Auinger P, Parkinson Study Group Determination of Minimal Clinically Important Change in Early and Advanced Parkinson's Disease. Mov Disord. 5(26) : 813-8., 2011.
  • Schapira, AH.Barone, P.Hauser, RA.Mizuno, Y.Rascol, O.Busse, M.Salin, L.Juhel, N.Poewe, W. Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial. Neurology. 77(8) : 767-74, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21832216
  • Butterfield LC, Cimino CR, Oelke LE, Hauser RA, Sanchez-Ramos J The independent influence of apathy and depression on cognitive functioning in Parkinson's disease. Neuropsychology. 6(24) : 721-30, 2010.
  • Hauser, RA.Schapira, AH.Rascol, O.Barone, P.Mizuno, Y.Salin, L.Haaksma, M.Juhel, N.Poewe, W. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society. 25(15) : 2542-9, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20669317
  • Rascol, O.Barone, P.Hauser, RA.Mizuno, Y.Poewe, W.Schapira, AH.Salin, L.Sohr, M.Debieuvre, C. Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society. 25(14) : 2326-32, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20669265
  • Lew, MF.Hauser, RA.Hurtig, HI.Ondo, WG.Wojcieszek, J.Goren, T.Fitzer-Attas, CJ. Long-term efficacy of rasagiline in early Parkinson's disease. The International journal of neuroscience. 120(6) : 404-8, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20504210
  • Hersh, BP.Earl, NL.Hauser, RA.Stacy, M. Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations. Movement disorders : official journal of the Movement Disorder Society. 25(7) : 927-31, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20461810
  • Watts, RL.Lyons, KE.Pahwa, R.Sethi, K.Stern, M.Hauser, RA.Olanow, W.Gray, AM.Adams, B.Earl, NL. Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society. 25(7) : 858-66, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20461803
  • Hauser, RA. Early pharmacologic treatment in Parkinson's disease. The American journal of managed care. 16 Suppl Implications: S100-7, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20297870
  • Colosimo, C.Martínez-Martín, P.Fabbrini, G.Hauser, RA.Merello, M.Miyasaki, J.Poewe, W.Sampaio, C.Rascol, O.Stebbins, GT.Schrag, A.Goetz, CG. Task force report on scales to assess dyskinesia in Parkinson's disease: critique and recommendations. Movement disorders : official journal of the Movement Disorder Society. 25(9) : 1131-42, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20310033
  • Bronzova, J.Sampaio, C.Hauser, RA.Lang, AE.Rascol, O.Theeuwes, A.van de Witte, SV.van Scharrenburg, G. Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society. 25(6) : 730-8, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20198713
  • Lyons, KE.Friedman, JH.Hermanowicz, N.Isaacson, SH.Hauser, RA.Hersh, BP.Silver, DE.Tetrud, JW.Elmer, LW.Parashos, SA.Struck, LK.Lew, MF.Pahwa, R. Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects. Clinical neuropharmacology. 33(1) : 5-10, 2010. http://www.ncbi.nlm.nih.gov/pubmed/19855267
  • Hauser, RA. New considerations in the medical management of early Parkinson's disease: impact of recent clinical trials on treatment strategy. Parkinsonism & related disorders. 15 Suppl 3: S17-21, 2009. http://www.ncbi.nlm.nih.gov/pubmed/20082983
  • Hauser, RA.Panisset, M.Abbruzzese, G.Mancione, L.Dronamraju, N.Kakarieka, A. Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society. 24(4) : 541-50, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19058133
  • Hauser, RA.Auinger, P.Oakes, D. Levodopa response in early Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society. 24(16) : 2328-36, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19908302
  • Jahan, I.Hauser, RA.Sullivan, KL.Miller, A.Zesiewicz, TA. Sleep disorders in Parkinson's disease. Neuropsychiatric disease and treatment. 5: 535-40, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19898667
  • Sethi, KD.Hauser, RA.Isaacson, SH.McClain, T. Levodopa/carbidopa/entacapone 200/50/200 mg (Stalevo 200) in the treatment of Parkinson's disease: a case series. Cases journal. 2: 7134, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19829918
  • Tanner, CM.Ross, GW.Jewell, SA.Hauser, RA.Jankovic, J.Factor, SA.Bressman, S.Deligtisch, A.Marras, C.Lyons, KE.Bhudhikanok, GS.Roucoux, DF.Meng, C.Abbott, RD.Langston, JW. Occupation and risk of parkinsonism: a multicenter case-control study. Archives of neurology. 66(9) : 1106-13, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19752299
  • Cicchetti, F.Saporta, S.Hauser, RA.Parent, M.Saint-Pierre, M.Sanberg, PR.Li, XJ.Parker, JR.Chu, Y.Mufson, EJ.Kordower, JH.Freeman, TB. Neural transplants in patients with Huntington's disease undergo disease-like neuronal degeneration. Proceedings of the National Academy of Sciences of the United States of America. 106(30) : 12483-8, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19620721
  • Seeberger, LC.Hauser, RA. Levodopa/carbidopa/entacapone in Parkinson's disease. Expert review of neurotherapeutics. 9(7) : 929-40, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19589043
  • Connors, JJ.Sacks, D.Furlan, AJ.Selman, WR.Russell, EJ.Stieg, PE.Hadley, MN.Wojak, JC.Koroshetz, WJ.Heros, RC.Strother, CM.Duckwiler, GR.Durham, JD.Tom-sick, TO.Rosenwasser, RH.McDougall, CG.Haughton, VM.Derdeyn, CP.Wechsler, LR.Hudgins, PA.Alberts, MJ.Raabe, RD.Gomez, CR.Cawley, CM.Krol, KL.Futrell, N.Hauser, RA.Frank, JI. Training, competency, and credentialing standards for diagnostic cervicocerebral angiography, carotid stenting, and cerebrovascular intervention: a joint statement from the American Academy of Neurology, the American Association of Neurological Surgeons, the American Society of Interventional and Therapeutic Neuroradiology, the American Society of Neuroradiology, the Congress of Neurological Surgeons, the AANS/CNS Cerebrovascular Section, and the Society of Interventional Radiology. Journal of vascular and interventional radiology : JVIR. 20(7 Suppl) : S292-301, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19560013
  • Zesiewicz, TA.Hauser, RA.Freeman, A.Sullivan, KL.Miller, AM.Halim, T. Fentanyl-induced bradykinesia and rigidity after deep brain stimulation in a patient with Parkinson disease. Clinical neuropharmacology. 32(1) : 48-50, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19471184
  • Hauser, RA.Bronzova, J.Sampaio, C.Lang, AE.Rascol, O.Theeuwes, A.van de Witte, SV. Safety and tolerability of pardoprunox, a new partial dopamine agonist, in a randomized, controlled study of patients with advanced Parkinson's disease. European neurology. 62(1) : 40-8, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19407454
  • Hauser, RA. Levodopa: past, present, and future. European neurology. 62(1) : 1-8, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19407449
  • Hauser, RA.Lyons, KE.McClain, T.Carter, S.Perlmutter, D. Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society. 24(7) : 979-83, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19230029
  • Simuni, T.Lyons, KE.Pahwa, R.Hauser, RA.Comella, C.Elmer, L.Weintraub, D. Treatment of early Parkinson's disease. Part 2. European neurology. 61(4) : 206-15, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19176961
  • Simuni, T.Lyons, KE.Pahwa, R.Hauser, RA.Comella, C.Elmer, L.Weintraub, D. Treatment of early Parkinson's disease. Part 1. European neurology. 61(4) : 193-205, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19176960
  • Hauser, RA.Lew, MF.Hurtig, HI.Ondo, WG.Wojcieszek, J.Fitzer-Attas, CJ. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society. 24(4) : 564-73, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19086083
  • Isaacson, SH.Hauser, RA. Improving symptom control in early Parkinson's disease. Therapeutic advances in neurological disorders. 2(6) : 29-41, 2009. http://www.ncbi.nlm.nih.gov/pubmed/21180628
  • Olanow, CW.Hauser, RA.Jankovic, J.Langston, W.Lang, A.Poewe, W.Tolosa, E.Stocchi, F.Melamed, E.Eyal, E.Rascol, O. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Movement disorders : official journal of the Movement Disorder Society. 23(15) : 2194-201, 2008. http://www.ncbi.nlm.nih.gov/pubmed/18932271
  • Kordower, JH.Chu, Y.Hauser, RA.Olanow, CW.Freeman, TB. Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. Movement disorders : official journal of the Movement Disorder Society. 23(16) : 2303-6, 2008. http://www.ncbi.nlm.nih.gov/pubmed/19006193
  • Shimberg, WR.Patel, NB.Sullivan, KL.Hauser, RA.Zesiewicz, TA. Levetiracetam for stiff-person syndrome: report of 2 patients. Clinical neuropharmacology. 31(5) : 301-2, 2008. http://www.ncbi.nlm.nih.gov/pubmed/18836351
  • Zesiewicz, TA.Shimberg, WR.Hauser, RA.Robinson, W.Wilson, MC.Sullivan, KL. Chorea as a side effect of gabapentin (Neurontin) in a patient with complex regional pain syndrome Type 1. Clinical rheumatology. 27(3) : 389-90, 2008. http://www.ncbi.nlm.nih.gov/pubmed/17938990
  • Goetz, CG.Wuu, J.McDermott, MP.Adler, CH.Fahn, S.Freed, CR.Hauser, RA.Olanow, WC.Shoulson, I.Tandon, PK.Leurgans, S. Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Movement disorders : official journal of the Movement Disorder Society. 23(5) : 690-9, 2008. http://www.ncbi.nlm.nih.gov/pubmed/18228568
  • Zesiewicz, TA.Sullivan, KL.Hoffmann, M.Benes, LM.Smith, DA.Ward, CL.Hauser, RA. Delayed thalamic intracranial hemorrhage in an essential tremor patient following deep brain stimulation. European neurology. 59(3-4) : 187-9, 2008. http://www.ncbi.nlm.nih.gov/pubmed/18230878
  • Kordower, JH.Chu, Y.Hauser, RA.Freeman, TB.Olanow, CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nature medicine. 14(5) : 504-6, 2008. http://www.ncbi.nlm.nih.gov/pubmed/18391962
  • Encarnacion, EV.Hauser, RA. Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments. European neurology. 60(2) : 57-66, 2008. http://www.ncbi.nlm.nih.gov/pubmed/18480609
  • Simon, DK.Swearingen, CJ.Hauser, RA.Trugman, JM.Aminoff, MJ.Singer, C.Truong, D.Tilley, BC. Caffeine and progression of Parkinson disease. Clinical neuropharmacology. 31(4) : 189-96, 2008. http://www.ncbi.nlm.nih.gov/pubmed/18670242
  • Hauser, RA.Shulman, LM.Trugman, JM.Roberts, JW.Mori, A.Ballerini, R.Sussman, NM. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. Movement disorders : official journal of the Movement Disorder Society. 23(15) : 2177-85, 2008. http://www.ncbi.nlm.nih.gov/pubmed/18831530
  • Seeberger, LC.Hauser, RA. Optimizing bioavailability in the treatment of Parkinson's disease. Neuropharmacology. 53(7) : 791-800, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17936857
  • Hauser, RA.Rascol, O.Korczyn, AD.Jon Stoessl, A.Watts, RL.Poewe, W.De Deyn, PP.Lang, AE. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Movement disorders : official journal of the Movement Disorder Society. 22(16) : 2409-17, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17894339
  • Simonson, W.Hauser, RA.Schapira, AH. Role of the pharmacist in the effective management of wearing-off in Parkinson's disease. The Annals of pharmacotherapy. 41(11) : 1842-9, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17878397
  • Zesiewicz, TA.Patel-Larson, A.Hauser, RA.Sullivan, KL. Social Security Disability Insurance (SSDI) in Parkinson's disease. Disability and rehabilitation. 29(24) : 1934-6, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17852221
  • Zesiewicz, TA.Sullivan, KL.Ward, CL.Hauser, RA. Tiagabine and exacerbation of essential tremor. Movement disorders : official journal of the Movement Disorder Society. 22(14) : 2132-3, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17663461
  • Zesiewicz, TA.Ward, CL.Hauser, RA.Sanchez-Ramos, J.Staffetti, JF.Sullivan, KL. A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor. Movement disorders : official journal of the Movement Disorder Society. 22(2) : 279-82, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17149715
  • Zesiewicz, TA.Ward, CL.Hauser, RA.Pease Campbell, JA.Sullivan, KL. Pregabalin (Lyrica) in the treatment of essential tremor. Movement disorders : official journal of the Movement Disorder Society. 22(1) : 139-41, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17089400
  • Sullivan, KL.Ward, CL.Hauser, RA.Zesiewicz, TA. Prevalence and treatment of non-motor symptoms in Parkinson's disease. Parkinsonism & related disorders. 13(8) : 545, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17188922
  • Samanta, J.Hauser, RA. Duodenal levodopa infusion for the treatment of Parkinson's disease. Expert opinion on pharmacotherapy. 8(5) : 657-64, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17376020
  • Hauser, RA.Zesiewicz, TA. Advances in the pharmacologic management of early Parkinson disease. The neurologist. 13(3) : 126-32, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17495756
  • Zesiewicz, TA.Ward, CL.Hauser, RA.Salemi, JL.Siraj, S.Wilson, MC.Sullivan, KL. A pilot, double-blind, placebo-controlled trial of pregabalin (Lyrica) in the treatment of essential tremor. Movement disorders : official journal of the Movement Disorder Society. 22(11) : 1660-3, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17580330
  • Zesiewicz, TA.Sullivan, KL.Hauser, RA. Levodopa-induced dyskinesia in Parkinson's disease: epidemiology, etiology, and treatment. Current neurology and neuroscience reports. 7(4) : 302-10, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17618536
  • Hauser, RA.Salin, L.Juhel, N.Konyago, VL. Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society. 22(3) : 359-65, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17149725


  • America'a Top Doctors (Top 1%) (Castle Connolly - 2013)
  • America'a Top Doctors (Top 1%) (Castle Connolly - 2012)
  • America's Top Doctors (Castle Connolly - 2011)
  • America's Top Doctors (Castle Connolly - 2010)
  • America's Top Doctors (Castle Connolly - 2009)
  • America's Top Doctors (Castle Connolly - 2008)
  • America's Top Doctors (Castle Connolly - 2008)
  • America's Top Doctors (Castle Connolly - 2007)
  • MIllion Dollar Researcher (University of South Florida - 2006)
  • America's Top Doctors (Castle Connolly - 2006)
  • Center of Excellence (National Parkinson Foundation - 2005)
  • America's Top Doctors (Castle Connolly - 2005)
  • America's Top Doctors (Castle Connolly - 2004)
  • America's Top Doctors (Castle Connolly - 2003)